DK3244909T3 - Proteasominhibitorer til at behandle en lidelse relateret til en akkumulering af ikke-degraderet unormalt protein eller en cancer - Google Patents
Proteasominhibitorer til at behandle en lidelse relateret til en akkumulering af ikke-degraderet unormalt protein eller en cancer Download PDFInfo
- Publication number
- DK3244909T3 DK3244909T3 DK16700619.6T DK16700619T DK3244909T3 DK 3244909 T3 DK3244909 T3 DK 3244909T3 DK 16700619 T DK16700619 T DK 16700619T DK 3244909 T3 DK3244909 T3 DK 3244909T3
- Authority
- DK
- Denmark
- Prior art keywords
- proteasomin
- degradated
- inhibitors
- cancer
- accumulation
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 230000002159 abnormal effect Effects 0.000 title 1
- 238000009825 accumulation Methods 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Birds (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15305026 | 2015-01-14 | ||
| PCT/EP2016/050678 WO2016113357A1 (en) | 2015-01-14 | 2016-01-14 | Proteasome inhibitors for treating a disorder related to an accumulation of non-degraded abnormal protein or a cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3244909T3 true DK3244909T3 (da) | 2020-01-13 |
Family
ID=52434704
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16700619.6T DK3244909T3 (da) | 2015-01-14 | 2016-01-14 | Proteasominhibitorer til at behandle en lidelse relateret til en akkumulering af ikke-degraderet unormalt protein eller en cancer |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20170368134A1 (da) |
| EP (1) | EP3244909B1 (da) |
| JP (2) | JP2018503632A (da) |
| CN (1) | CN107405378B (da) |
| AU (1) | AU2016208001B2 (da) |
| BR (1) | BR112017015059A2 (da) |
| CA (1) | CA2972740A1 (da) |
| CY (1) | CY1122583T1 (da) |
| DK (1) | DK3244909T3 (da) |
| ES (1) | ES2764452T3 (da) |
| HU (1) | HUE047603T2 (da) |
| PL (1) | PL3244909T3 (da) |
| PT (1) | PT3244909T (da) |
| SG (1) | SG11201705108TA (da) |
| WO (1) | WO2016113357A1 (da) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9163284B2 (en) | 2013-08-09 | 2015-10-20 | President And Fellows Of Harvard College | Methods for identifying a target site of a Cas9 nuclease |
| US9228207B2 (en) | 2013-09-06 | 2016-01-05 | President And Fellows Of Harvard College | Switchable gRNAs comprising aptamers |
| US9322037B2 (en) | 2013-09-06 | 2016-04-26 | President And Fellows Of Harvard College | Cas9-FokI fusion proteins and uses thereof |
| US20150165054A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting caspase-9 point mutations |
| EP2908137A1 (en) | 2014-02-14 | 2015-08-19 | Institut Pasteur | Methods for in vitro investigating mitochondrial replication dysfunction in a biological sample, kits and uses thereof, therapeutic methods against progeroid-like syndromes or symptomes and screening method for identifying particular protease inhibitor(s) and/or nitroso-redox stress scavenger compound(s) |
| US10077453B2 (en) | 2014-07-30 | 2018-09-18 | President And Fellows Of Harvard College | CAS9 proteins including ligand-dependent inteins |
| IL310721B2 (en) | 2015-10-23 | 2025-11-01 | Harvard College | Nucleobase editors and uses thereof |
| CN110214183A (zh) | 2016-08-03 | 2019-09-06 | 哈佛大学的校长及成员们 | 腺苷核碱基编辑器及其用途 |
| WO2018031683A1 (en) | 2016-08-09 | 2018-02-15 | President And Fellows Of Harvard College | Programmable cas9-recombinase fusion proteins and uses thereof |
| US11542509B2 (en) | 2016-08-24 | 2023-01-03 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
| KR102622411B1 (ko) | 2016-10-14 | 2024-01-10 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 핵염기 에디터의 aav 전달 |
| WO2018119359A1 (en) | 2016-12-23 | 2018-06-28 | President And Fellows Of Harvard College | Editing of ccr5 receptor gene to protect against hiv infection |
| ES2923022T3 (es) * | 2017-01-31 | 2022-09-22 | Univ Leland Stanford Junior | Agentes que inhiben Ngly1 y métodos de uso de los mismos |
| EP3592853A1 (en) | 2017-03-09 | 2020-01-15 | President and Fellows of Harvard College | Suppression of pain by gene editing |
| US12390514B2 (en) | 2017-03-09 | 2025-08-19 | President And Fellows Of Harvard College | Cancer vaccine |
| US11542496B2 (en) | 2017-03-10 | 2023-01-03 | President And Fellows Of Harvard College | Cytosine to guanine base editor |
| KR20240116572A (ko) | 2017-03-23 | 2024-07-29 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 핵산 프로그램가능한 dna 결합 단백질을 포함하는 핵염기 편집제 |
| US11560566B2 (en) | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
| CN111801345A (zh) | 2017-07-28 | 2020-10-20 | 哈佛大学的校长及成员们 | 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物 |
| EP3676376B1 (en) | 2017-08-30 | 2025-01-15 | President and Fellows of Harvard College | High efficiency base editors comprising gam |
| KR20250107288A (ko) | 2017-10-16 | 2025-07-11 | 더 브로드 인스티튜트, 인코퍼레이티드 | 아데노신 염기 편집제의 용도 |
| US12406749B2 (en) | 2017-12-15 | 2025-09-02 | The Broad Institute, Inc. | Systems and methods for predicting repair outcomes in genetic engineering |
| US12157760B2 (en) | 2018-05-23 | 2024-12-03 | The Broad Institute, Inc. | Base editors and uses thereof |
| US12522807B2 (en) | 2018-07-09 | 2026-01-13 | The Broad Institute, Inc. | RNA programmable epigenetic RNA modifiers and uses thereof |
| WO2020051360A1 (en) * | 2018-09-05 | 2020-03-12 | The Broad Institute, Inc. | Base editing for treating hutchinson-gilford progeria syndrome |
| WO2020092453A1 (en) | 2018-10-29 | 2020-05-07 | The Broad Institute, Inc. | Nucleobase editors comprising geocas9 and uses thereof |
| US12351837B2 (en) | 2019-01-23 | 2025-07-08 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| WO2020191233A1 (en) | 2019-03-19 | 2020-09-24 | The Broad Institute, Inc. | Methods and compositions for editing nucleotide sequences |
| CA3132348A1 (en) * | 2019-04-10 | 2020-10-15 | Dana-Farber Cancer Institute, Inc. | Degraders of fibroblast growth factor receptor 2 (fgfr2) |
| US12473543B2 (en) | 2019-04-17 | 2025-11-18 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| US12435330B2 (en) | 2019-10-10 | 2025-10-07 | The Broad Institute, Inc. | Methods and compositions for prime editing RNA |
| IL297761A (en) | 2020-05-08 | 2022-12-01 | Broad Inst Inc | Methods and compositions for simultaneously editing two helices of a designated double-helix nucleotide sequence |
| CN112007160A (zh) * | 2020-08-17 | 2020-12-01 | 暨南大学 | 蛋白酶体抑制剂在抗癌药物中的应用 |
| KR20230156016A (ko) * | 2020-11-24 | 2023-11-13 | 프로게라이프 | 분절성 프로제로이드 증후군 치료용 화합물 |
| CN116688129A (zh) * | 2023-05-24 | 2023-09-05 | 中山大学附属第一医院 | 靶向苯丙酮酸促进糖尿病伤口愈合以及抑制过度nlrp3炎症小体的激活 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8999289B2 (en) * | 2005-03-22 | 2015-04-07 | President And Fellows Of Harvard College | Treatment of protein degradation disorders |
| IL177989A0 (en) * | 2006-09-10 | 2006-12-31 | Yeda Res & Dev | Use of transcription factor inhibitor in the manufacture of a medicament |
| WO2008148016A1 (en) * | 2007-05-25 | 2008-12-04 | University Of Pittsburgh- Of The Commonwealth System Of Higher Education | Inhibiting the signs of aging by inhibiting nf-kappa b activation |
| FR2926020B1 (fr) * | 2008-01-03 | 2010-08-13 | Univ Aix Marseille Ii | Composition cosmetique et/ou dermatologique |
| US20130053323A1 (en) * | 2009-12-22 | 2013-02-28 | Emma Eriksson | Methods and use related to humanin and humanin-like peptides |
| US20140161785A1 (en) * | 2012-12-10 | 2014-06-12 | Feiyan Liu | Verticillin A Inhibition of Histone Methyltransferases |
-
2016
- 2016-01-14 CA CA2972740A patent/CA2972740A1/en not_active Abandoned
- 2016-01-14 PT PT167006196T patent/PT3244909T/pt unknown
- 2016-01-14 AU AU2016208001A patent/AU2016208001B2/en not_active Ceased
- 2016-01-14 PL PL16700619T patent/PL3244909T3/pl unknown
- 2016-01-14 BR BR112017015059-0A patent/BR112017015059A2/pt not_active IP Right Cessation
- 2016-01-14 ES ES16700619T patent/ES2764452T3/es active Active
- 2016-01-14 JP JP2017535453A patent/JP2018503632A/ja active Pending
- 2016-01-14 WO PCT/EP2016/050678 patent/WO2016113357A1/en not_active Ceased
- 2016-01-14 HU HUE16700619A patent/HUE047603T2/hu unknown
- 2016-01-14 CN CN201680005810.3A patent/CN107405378B/zh not_active Expired - Fee Related
- 2016-01-14 EP EP16700619.6A patent/EP3244909B1/en active Active
- 2016-01-14 US US15/543,196 patent/US20170368134A1/en not_active Abandoned
- 2016-01-14 DK DK16700619.6T patent/DK3244909T3/da active
- 2016-01-14 SG SG11201705108TA patent/SG11201705108TA/en unknown
-
2019
- 2019-12-27 CY CY20191101357T patent/CY1122583T1/el unknown
-
2020
- 2020-03-31 JP JP2020063619A patent/JP2020121980A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20170368134A1 (en) | 2017-12-28 |
| AU2016208001A1 (en) | 2017-07-13 |
| BR112017015059A2 (pt) | 2019-05-14 |
| PT3244909T (pt) | 2020-01-15 |
| JP2020121980A (ja) | 2020-08-13 |
| WO2016113357A1 (en) | 2016-07-21 |
| CA2972740A1 (en) | 2016-07-21 |
| ES2764452T3 (es) | 2020-06-03 |
| SG11201705108TA (en) | 2017-07-28 |
| HUE047603T2 (hu) | 2020-04-28 |
| PL3244909T3 (pl) | 2020-04-30 |
| EP3244909A1 (en) | 2017-11-22 |
| JP2018503632A (ja) | 2018-02-08 |
| CN107405378B (zh) | 2021-09-24 |
| EP3244909B1 (en) | 2019-10-09 |
| CY1122583T1 (el) | 2021-01-27 |
| WO2016113357A8 (en) | 2017-09-08 |
| CN107405378A (zh) | 2017-11-28 |
| AU2016208001B2 (en) | 2021-05-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3244909T3 (da) | Proteasominhibitorer til at behandle en lidelse relateret til en akkumulering af ikke-degraderet unormalt protein eller en cancer | |
| IL263586B (en) | Inhibitors of the menin-mll interaction | |
| EP3377059A4 (en) | INHIBITORS OF CXCR2 | |
| LT3303334T (lt) | Tirozinkinazės inhibitoriai | |
| DK3371171T3 (da) | Inhibitorer af RET | |
| DK3102576T3 (da) | Dihydropyrrolopyridininhibitorer af ror-gamma | |
| DK3286311T3 (da) | Fremgangsmåde til behandling af maligniteter | |
| MA44474A (fr) | Nouveaux inhibiteurs de la ferroportine | |
| DK3317400T3 (da) | Fremgangsmåde til kryokonservering af tumorinfiltrerende lymfocytter | |
| HUE052106T2 (hu) | Eljárás rák kezelésére | |
| DK3256594T3 (da) | Forbedret fremføring af viruspartikler til striatum og cortex | |
| DK3160956T3 (da) | Inhibitorer af lysin-specifik demethylase-1 | |
| DK3244891T3 (da) | Forbindelser til forbedring af mrna-splejsning | |
| DK3331876T3 (da) | Modulators of ror-gamma | |
| DK3164380T3 (da) | Hæmmere af lysinspecifik demethylase-1 | |
| IL254779A0 (en) | Methods of administering glutaminase inhibitors | |
| DK3368683T3 (da) | Fremgangsmåde til kvantifikationen af pd-l1 | |
| EP3313828A4 (en) | METALLO-BETA-Lactamase INHIBITORS | |
| DK3397648T3 (da) | Fremgangsmåde til deacetylering af biopolymerer | |
| DK3261726T3 (da) | Sammensætning til behandling af acne | |
| DK3371165T3 (da) | Btk-inhibitor til anvendelse til behandling af kræft | |
| DK3512857T3 (da) | Spiro-bicykliske inhibitorer af menin-mll-interaktion | |
| DK3164394T3 (da) | Gls1-inhibitorer til behandling af sygdomme | |
| DK3283210T3 (da) | Fremgangsmåde | |
| PL3393468T3 (pl) | Metody leczenia niedoboru odporności |